NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 7,529 shares, a decline of 16.5% from the January 15th total of 9,014 shares. Based on an average daily trading volume, of 647 shares, the short-interest ratio is presently 11.6 days. Based on an average daily trading volume, of 647 shares, the short-interest ratio is presently 11.6 days.

NeuroSense Therapeutics Trading Up 6.6%

Shares of NASDAQ NRSNW traded up $0.01 during trading hours on Monday, hitting $0.20. 900 shares of the stock were exchanged, compared to its average volume of 2,350. NeuroSense Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.00. The firm has a fifty day moving average price of $0.32 and a 200-day moving average price of $0.40.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.